Vortrag
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide & Liraglutide in Type 2 Diabetes Patients (TROPHIES): final 24-month primary endpoint analysis
Speaker
Vortrag
Achievement of HbA1c ≤6.5% (47.5mmol/mol), with ≥10% weight loss, without hypoglycemia in patients treated with tirzepatide vs. comparators in SURPASS program
Speaker
